Article can be read via the following link: https://www.businesswire.com/news/home/20250109147839/en/Cyrus-Biotechnology-Announces-Selection-of-CYR212-as-Clinical-Candidate-for-Chronic-IgG-driven-Autoimmune-Disease-Including-Myasthenia-Gravis-and-Immune-Thrombocytopenia

https://www.businesswire.com/news/home/20240611967134/en/Cyrus-Biotechnology-Spins-out-Levitate-Bio-a-Protein-AI-Bioinformatics-and-Rosetta-Service-Provider-to-Bring-Automated-Customized-AI-Solutions-to-Biopharma-Drug-Discovery

Read article at the link below: https://www.businesswire.com/news/home/20241211633894/en/Cyrus-Biotechnology-Announces-Potent-in-vivo-Redosability-of-an-Engineered-IdeS-Protease-for-IgG-driven-Autoimmune-Disease-Demonstrating-No-Anti-drug-Antibodies

Cyrus CSO and co-founder Yifan Song performed a presentation at the Hit ID Summit in Boston, speaking on a few topics including Cyrus’ hybrid AI/screening platform in risk mitigation of protein therapeutics, …

Cyrus co-founder and Computational Biologist David Baker was recently awarded as a 2024 Nobel Laureate in Chemistry. Congratulations to David on receiving such a prestigious honor. Here is the link to the …

Director of Discovery Dr. Erik Procko recently performed a presentation on Cyrus’ novel IgG-degrading IdeS enzyme development candidates at PepTalk Conference San Diego on January 16th. The article can be found via …